Journal article

Clinical management of catecholaminergic polymorphic ventricular tachycardia the role of left cardiac sympathetic denervation

GM De Ferrari, V Dusi, C Spazzolini, JM Bos, DJ Abrams, CI Berul, L Crotti, AM Davis, M Eldar, M Kharlap, A Khoury, AD Krahn, A Leenhardt, CR Moir, A Odero, LO Nordkamp, T Paul, F Rosés I Noguer, M Shkolnikova, J Till Show all

Circulation | Published : 2015

Abstract

Background-Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disorder causing life-threatening arrhythmias whenever sympathetic activity increases. β-Blockers are the mainstay of therapy; when they fail, implantable cardioverter-defibrillators (ICDs) are used but often cause multiple shocks. Preliminary results with flecainide appear encouraging. We proposed left cardiac sympathetic denervation (LCSD) as useful additional therapy, but evidence remains anecdotal. Methods and Results-We report 63 patients with CPVT who underwent LCSD as secondary (n=54) or primary (n=9) prevention. The median post-LCSD follow-up was 37 months. The 9 asymptomatic patients remained free o..

View full abstract

University of Melbourne Researchers